In: Cancer treatment reviews, 2020, vol. 90, p. 11
The DNA damage response (DDR) is a well-coordinated cellular network activated by DNA damage. The unravelling of the key players in DDR, their specific inactivation in different tumor types and the synthesis of specific chemical inhibitors of DDR represent a new hot topic in cancer therapy. In this article, we will review the importance of DDR in lymphoma development and how this can be...
|
In: European Journal of Epidemiology, 2015, vol. 30, no. 12, p. 1263-1275
|
In: Abdominal Imaging, 2015, vol. 40, no. 6, p. 1997-2011
|
In: Cancers, 2019, vol. 11, no. 6, p. 775
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56...
|
In: Non-coding RNA, 2019, vol. 5, no. 3, p. 47
Diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) are the most common B-cell lymphomas (BCL) in dogs. Recent investigations have demonstrated overlaps of these histotypes with the human counterparts, including clinical presentation, biologic behavior, tumor genetics, and treatment response. The molecular mechanisms that underlie canine BCL are...
|
In: International journal of molecular sciences, 2020, vol. 21, no. 3, p. 21 p
The activation of the PI3K/AKT/mTOR pathway is a main driver of cell growth, proliferation, survival, and chemoresistance of cancer cells, and, for this reason, represents an attractive target for developing targeted anti- cancer drugs. There are plenty of preclinical data sustaining the anti-tumor activity of dual PI3K/mTOR inhibitors as single agents and in combination in lymphomas. Clinical...
|
In: Oncotarget, 2017, vol. 8, no. 49, p. 85068-85084
Diffuse large B cell lymphoma (DLBCL) is the most frequent lymphoma accounting for more than the 30% of the cases. Involvement of extranodal sites, such as bone marrow and central nervous system, is associated with poor prognosis. A contribution of the chemokine system in these processes is assumed as it is known as a critical regulator of the metastatic process in cancer. The atypical...
|
In: Supportive Care in Cancer, 2008, vol. 16, no. 4, p. 339-345
|
|
In: Mund-, Kiefer- und Gesichtschirurgie, 2005, vol. 9, no. 1, p. 48-52
|